Faculty Information

Click to View Virtual Tour

Faculty Information

Anthony Vernillo, D.D.S, PhD., MBE
Professor
Oral and Maxillofacial Pathology, Radiology and Medicine
838 Schwartz, 345 East 24 Street
Phone: 212-998-9859
Fax: 212-995-4087
E-mail:

Education:

1972 BA (Biology) New York University
1977 DDS (Dentistry) Case Western Reserve University
1979 Certificate (Oral Pathology) Zoller Memorial Dental Clinics, The University of Chicago
1982 PhD (Pathology) Graduate Division of the Biological Sciences, The University of Chicago
1984 Postdoctoral Research Associate (Cell Biology) Yale University School of Medicine
2005 MBE (Master of Bioethics) School of Medicine and Center for Bioethics, University of Pennsylvania

Research Interests / Professional Overview:

Hospital Affiliations
Member, Ethics Committee, Manhattan Veterans Administration Hospital, NY
Ethics Consultant, Bryn Mawr Hospital, PA

Professional Overview/Research Interests
Dr. Anthony Vernillo has been a full time faculty member at New York University College of Dentistry (NYUCD) since 1984. His past research investigations focused on the role of connective tissue degrading enzymes in the pathological remodeling of bone and the inhibitory effect of tetracyclines on bone resorption. Dr. Vernillo’s clinical interest in Oral Medicine has focused on the dental management of patients with diabetes mellitus as well as its oral and systemic complications. He has received grant funding from the NIH and other sources; published in refereed journals and book chapters; and presented at national and international meetings and universities abroad. Dr. Vernillo has provided dental care in outreach programs to Tanzania. He has received numerous teaching awards, including the Distinguished Teaching Award from New York University in 2002. Dr. Vernillo’s current objectives include research, teaching, and curriculum development in Bioethics.

Pub Med Articles:

Vernillo AT

Representative Publications:

Kerjaschki D, Vernillo AT, Farquhar MG. Defective glycosylation of podocalyxin—the
major glomerular sialoprotein in puromycin nephrosis. The American Journal of Pathology 118(3):343-349, 1985.

Vernillo AT, Schwartz NB. Stimulation of collagen and glycosaminoglycan production by phenytoin (5,5 diphenylhydantoin) in monolayer cultures of mesenchymal cells derived from embryonic chick sternae. Archives of Oral Biology 31(12):819-823, 1986.

Vernillo AT, Schwartz NB. The effects of phenytoin (5,5-diphenylhydantoin) on human gingival fibroblasts in culture. Journal of Periodontal Research 22:307-312, 1987.

Dziak R, Vernillo AT, Rifkin BR. The effects of phenytoin on calcium uptake in osteoblastic cells. Journal of Bone and Mineral Research 3:415-420, 1988.

Vernillo AT, Ramamurthy NS, Lee HM, Rifkin BR. The effect of phenytoin on collagenase and gelatinase activities in UMR 106-01 rat osteoblastic osteosarcoma cells.
Matrix 10:27-32. 1990.

Vernillo AT, Rifkin BR, Hauschka PV. Phenytoin affects osteocalcin secretion from osteoblastic rat osteosarcoma 17/2.8 cells in culture. Bone 11:309-312, 1990

Rifkin BR, Vernillo AT, Kleckner AP, Auszmann J, Rosenberg LR, Zimmerman M. Cathepsin B and L activities in isolated osteoclasts. Biochemical Biophysical Research Communications 179:63-69, 1991.

Rifkin BR, Vernillo AT, Golub LM. Blocking periodontal disease progression by inhibiting tissue-destructive enzymes: a potential therapeutic role for tetracyclines and their chemically-modified analogs. J. Periodontology 64:819-827, 1993.

Vernillo AT, Ramamurthy NS, Golub LM, Rifkin BR.: The nonantimicrobial properties of tetracycline for the treatment of periodontal disease. Current Opinion Periodontology 2:111-118, 1994.

Rifkin BR, Vernillo AT, Golub LM, Ramamurthy NS.: Modulation of bone resorption by tetracyclines. Annals New York Academy of Sciences 732:165-180, 1994.

Vernillo AT, Rifkin BR.: Effects of tetracyclines on bone metabolism. Advances in Dental Research 12: 56-62, 1998.

Sorsa T, Ramamurthy NS, Vernillo AT, Zhang X, Konttinen YT, Rifkin BR, Golub LM.
Functional sites of chemically-modified tetracyclines: Inhibition of the oxidative activation of human neutrophil and chicken osteoclast pro-matrix-metalloproteinases. J Rheumatology 25:975-982, 1998.

Vernillo AT. Diabetes mellitus: Relevance to Dental Treatment. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 91(3):263-270, 2001.

Ramamurthy NS, Rifkin BR, Greenwald RA, Xu J, Liu Y, Turner G, Golub LM, Vernillo AT. Inhibition of matrix metalloproteinase-mediated periodontal bone loss in rats: A comparison of 6 chemically modified tetracyclines. J. Periodontology 73(7):726-734, 2002.

Vernillo AT. Practicing for life. The dentist’s role in managing the diabetic patient. Nexus 5(2): 16-17, 2003.

Vernillo AT. Dental considerations for the treatment of patients with diabetes mellitus. JADA 134 (special edition):24S-33S, 2003

Robertson C, Drexler, AJ, Vernillo, AT. Update on diabetes diagnosis and management. JADA 134:16S-23S, 2003.

Selected Chapters/Books

Rifkin BR, Golub LM, Ramamurthy NS, Vernillo AT (1996). Inhibition of bone resorption by tetracyclines. In: The Biological Mechanisms of Tooth Movement and Craniofacial Adaptation, (Davidovitch Z. ed.), pp. 357-363. Harvard Society for the Advancement of Orthodontics, Boston, USA.

Vernillo AT, Ramamurthy NS, Golub LM, Greenwald RA, Rifkin BR (1997). Tetracyclines as inhibitors of bone loss in vivo. In: Studies in Stomatology and Craniofacial Biology (Baum B.J., Cohen Jr. M.M. eds.), Chapter 29, pp. 499-522, IOS Press, Amsterdam.

Vernillo A, Rifkin B (1998). Collagenase and other osteoblast enzymes. In: Advances in Organ Biology. (Zaidi M. ed.) JAI Press, Greenwich. Volume 5B, Chapter 22, pp. 467-482.

Touger-Decker R, Sirois DA, Vernillo AT (2004). Diabetes Mellitus. Nutrition and Oral Health Relationships. In: Nutrition and Oral Medicine (Touger-Decker R., Sirois DA., Mobley C., eds.), Humana Press, Inc., Totowa, NJ. Section IV. Select Diseases/Conditions with Known Nutrition and Oral Health Relationships. Chapter 11, pp. 185-204.

Ibsen OAC, Phelan JA, Vernillo AT (2009). Oral manifestations of systemic disease. In: Oral Pathology for the Dental Hygienist. (Ibsen O.A.C., Phelan J.A. eds), Chapter 9, An Imprint of Elsevier Science, St. Louis, MO. Fifth Edition.

Selected Publications/Original Papers—Bioethics

Vernillo AT. Ethics, Integrity and an Aristotelian Roadmap to Moral Excellence. Global Health Nexus 8(2): 16-19, 2006.

Vernillo AT, Wolpe PR, Halpern SD. Re-examining ethical obligations in the intensive care unit: HIV disclosure to surrogates. Critical Care 11(2):125-127, 2007. (DOI: 10.1186/cc5720)

Vernillo AT, Wolpe PR, Halpern SD. [Response to Letter]. Lott JP. HIV disclosure to surrogate decision makers: privacy versus presumption. Critical Care 11(3):416-417, 2007. (DOI: 10.1186/cc5927)

Vernillo AT, Caplan AL. Routine HIV testing in dental practice: Can we cross the Rubicon? J Dental Education 71(12):1534-1539, 2007.

Vernillo A. Neuroethics is not hyperbole. American Journal of Bioethics (AJOB Neuroscience) 8(1):57-59, 2008. (DOI: 10.1080/15265160701828535)

Vernillo A. Preventive ethics and rural healthcare: Addressing issues on a systems level. American Journal of Bioethics 8(4):61-62, 2008. (DOI: 10.1080/15265160802147116)

Vernillo A. Pragmatism as a complementary approach to legislation: Closing regulatory gaps in human subject research. American Journal of Bioethics 8(11): 15-17, 2008. (DOI: 10.1080/15265160802495614)

Vernillo A. Disclosure of adverse clinical trial results—should legal immunity be granted to drug companies? American Journal of Bioethics (2009) 9(8): 45-47 (DOI: 10.1080/15265160902939933)

Vernillo A. (2009) Placebos in Clinical Practice and the Power of Suggestion. American Journal of Bioethics 9(12):48-49.